Receptos Inc  

(Public, NASDAQ:RCPT)   Watch this stock  
Find more results for NYSE:RCPT
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -5.89
Shares 31.61M
Beta     -
Inst. own 100%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -1948.64%
Operating margin - -1891.02%
EBITD margin - -1887.02%
Return on average assets -41.50% -30.69%
Return on average equity -44.89% -32.84%
Employees 68 -
CDP Score - -


3033 Science Park Road, Suite 300
United States - Map
+1-858-6525700 (Phone)
+1-858-5872659 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn’s Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.